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Anesthetic-induced improvement of the inflammatory response
to one-lung ventilation
Abstract
BACKGROUND: Although one-lung ventilation (OLV) has become an established procedure during
thoracic surgery, sparse data exist about inflammatory alterations in the deflated, reventilated lung. The
aim of this study was to prospectively investigate the effect of OLV on the pulmonary inflammatory
response and to assess possible immunomodulatory effects of the anesthetics propofol and sevoflurane.
METHODS: Fifty-four adults undergoing thoracic surgery with OLV were randomly assigned to receive
either anesthesia with intravenously applied propofol or the volatile anesthetic sevoflurane. A
bronchoalveolar lavage was performed before and after OLV on the lung side undergoing surgery.
Inflammatory mediators (tumor necrosis factor alpha, interleukin 1beta, interleukin 6, interleukin 8,
monocyte chemoattractant protein 1) and cells were analyzed in lavage fluid as the primary endpoint.
The clinical outcome determined by postoperative adverse events was assessed as the secondary
endpoint. RESULTS: The increase of inflammatory mediators on OLV was significantly less
pronounced in the sevoflurane group. No difference in neutrophil recruitment was found between the
groups. A positive correlation between neutrophils and mediators was demonstrated in the propofol
group, whereas this correlation was missing in the sevoflurane group. The number of composite adverse
events was significantly lower in the sevoflurane group. CONCLUSIONS: This prospective,
randomized clinical study suggests an immunomodulatory role for the volatile anesthetic sevoflurane in
patients undergoing OLV for thoracic surgery with significant reduction of inflammatory mediators and
a significantly better clinical outcome (defined by postoperative adverse events) during sevoflurane
anesthesia.
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ABSTRACT 
Background: Although one-lung ventilation (OLV) has become an 
established procedure during thoracic surgery, sparse data exist about 
inflammatory alterations in the deflated, re-ventilated lung. The aim of this 
study was to prospectively investigate the effect of OLV on the pulmonary 
inflammatory response, and to assess possible immunmodulatory effects of 
the anesthetics propofol and sevoflurane. 
Methods: 54 adults undergoing thoracic surgery with OLV were randomly 
assigned to receive either anesthesia with intravenously applied propofol or 
the volatile anesthetic sevoflurane. A bronchoalveolar lavage was performed 
before and after OLV at the lung side undergoing surgery. Inflammatory 
mediators (tumor necrosis factor-, interleukin-1, interleukin-6, interleukin-8, 
monocyte chemoattractant protein-1) and cells were analyzed in lavage fluid 
as primary endpoint. The clinical outcome determined by postoperative 
adverse events was assessed as secondary endpoint. 
Results: The increase of inflammatory mediators upon OLV was significantly 
less pronounced in the sevoflurane group. While no difference in neutrophil 
recruitment was found between the groups, a positive correlation between 
neutrophils and mediators was demonstrated in the propofol group, whereas 
this correlation was missing in the sevoflurane group. The number of 
composite adverse events was significantly lower in the sevoflurane group. 
Conclusions: This prospectively randomized clinical study suggests an 
immunomodulatory role for the volatile anesthetic sevoflurane in patients 
undergoing OLV for thoracic surgery with significant reduction of inflammatory 
mediators and a significantly better clinical outcome (defined by postoperative 
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adverse events) under sevoflurane anesthesia.
 5
INTRODUCTION 
One-lung ventilation (OLV) has become a standard procedure for many 
interventions in thoracic surgery with a need for deflation of the lung in order 
to facilitate the surgical procedure. Experimental and clinical studies have 
shown that mechanical ventilation with increased tidal volume and airway 
pressure can induce a proinflammatory reaction in the non-deflated, ventilated 
lung 1-3. However, only limited data exist on inflammatory alterations in the 
temporarily deflated, non-ventilated and thus atelectatic lung in patients 
undergoing thoracic surgery. 
Several studies have shown that airway epithelial cells express and 
secrete various immune molecules such as adhesion molecules (intercellular 
adhesion molecule-1, ICAM-1), cytokines (tumor necrosis factor-, TNF-; 
interleukin-1, IL-1; interleukin-6, IL-6; interleukin-8, IL-8) and chemokines 
(cytokine-induced neutrophil chemoattractant-1, CINC-1; monocyte 
chemoattractant protein-1, MCP-1) 4-6. TNF-, IL-1, IL-6, IL-8, and obviously 
also MCP-1 are important  chemoattractants which are responsible for 
recruitment of effector cells such as neutrophils and alveolar macrophages 7,8. 
Through the expression and production of these inflammatory mediators the 
airway epithelium is thought to play an important role in the initiation and 
exacerbation of an inflammatory response within the airways. 
Atelectasis is a major cause for alveolar hypoxia. Funakoshi et al. 
demonstrated increased whole lung cytokine production in a rabbit model of 
short term atelectasis, followed by re-ventilation 9. However, no direct 
measurements upon atelectasis were performed without assessing the effect 
of re-ventilation. Another study focused on the inflammatory reaction in 
alveolar macrophages in the airway compartment under alveolar hypoxia 10. 
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OLV was performed for 60 min. Immediately after OLV alveolar macrophages 
were harvested and analyzed in culture. Cells from the deflated, non-
ventilated lung showed increased IL-1 and TNF levels compared with the non-
deflated, ventilated control lung. These results illustrated for the first time the 
consequences of atelectasis without evaluation of changes due to re-
ventilation. However, no studies have been performed so far elucidating this 
problem in a clinical setting. 
Volatile anesthetics, such as sevoflurane and isoflurane, have been 
shown to attenuate cardiac injury upon ischemia-reperfusion 11. Lee et al. 
recently described direct anti-inflammatory and anti-necrotic effects of 
sevoflurane in cultured human kidney cells following injury 12. Sevoflurane 
attenuated expression of inflammatory mediators as well as neutrophil 
accumulation in a model of endotoxin-induced injury in alveolar epithelial cells 
(AEC) in vitro 13. In addition, Reuterhaus et al. observed an anti-inflammatory 
effect of isoflurane in a model of endotoxin-induced lung injury in vivo 14. 
Finally, a recent study in patients indicated an immunomodulatory effect of the 
volatile anesthetic desflurane in the non-deflated, ventilated lung with high 
tidal volumes during OLV 15. 
 The objective of this prospective, randomized clinical study was to 
elucidate the impact of OLV on the pulmonary inflammatory response in the 
atelectatic lung and to assess possible immunomodulatory effects of the 
volatile anesthetic sevoflurane under these conditions. Increase of 
inflammatory mediators in broncholalveolar lavage fluid (BALF) was 
determined as primary endpoint, postoperative complications as secondary 
endpoint. The research hypothesis was that sevoflurane attenuates hypoxia 
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(OLV)-induced pulmonary inflammation assessed by decreased production of 
inflammatory mediators in the non-ventilated, deflated lung. 
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MATERIAL AND METHODS 
 
The study was approved by the institutional review board (Zurich, Switzerland) 
for human studies and internationally registered at ClinicalTrials.gov 
NCT00515905. The manuscript complies with the CONSORT requirements. 
Written informed patient consent was obtained from all participants. We 
studied 54 adults with American Society of Anesthesiologists physical status I-
III, scheduled for elective thoracic surgery with lung resection, performed 
through thoracotomy or thoracoscopy, requiring OLV during surgery (Fig. 1). 
Patients were randomly assigned to receive either total intravenous 
anesthesia with propofol (propofol group, n = 27) or inhalative anesthesia with 
sevoflurane (sevoflurane group, n = 27). 
Exclusion criteria were ongoing treatment with any dose of systemic or 
topical steroids, acute pulmonary or extrapulmonary infections (elevated C 
reactive protein, CRP > 10 ng/ml (reference: < 5 ng/ml), or leukocytosis > 10 x 
103/μl, (reference: 3.0 – 9.6 x 103/μl), severe chronic obstructive pulmonary 
disease (Gold stage 2 - 4), history of recurrent pneumothoraces, 
pneumomectomy and/or lung-volume-reduction-surgery. 
 
Anesthesia 
All patients received premedication with oral midazolam 7.5 mg one hour 
before the induction of anesthesia. In patients undergoing thoracotomy, and 
lacking general contraindications for regional anesthesia, a thoracic epidural 
catheter was inserted at Th4/5 to Th7/8 for intra- and postoperative pain 
management and was started with a continuous infusion rate of 5 - 8 ml/h 
ropivacaine 0.33%. 
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Induction of anesthesia was initiated with the intravenous anesthetic 
propofol target-controlled-infusion technique in the propofol group with target 
concentrations of 3 - 5 g/ml or with propofol administered as bolus (1.5 - 2.5 
mg/kg) in the sevoflurane group. Tracheal intubation was facilitated using 
fentanyl (3 g/kg) and atracurium (0.5 mg/kg) in both groups. Maintenance of 
anesthesia was performed with either propofol-target-controlled-infusion with 
a 1 minimum alveolar concentration-awake (age adjusted) or with sevoflurane 
(1 minimum alveolar concentration, age adjusted) according to randomization. 
Intraoperative pain-management was continued with intravenous application 
of fentanyl 1 – 2 g/kg boluses according to clinical needs and with 
continuous epidural infusion of ropivacaine 0.33% (5 – 8 ml/h) in patients with 
thoracic epidural anesthesia. Additionally, remifentanil 0.1 - 0.3 μg/kg/min was 
used. For further muscle relaxation, atracurium (bolus administrations of 10 
mg) was applied as clinically required.  
In both groups, a left- or right-sided double-lumen endobronchial tube 
(DLT, 37 – 41 Ch; Pharmaceutiques Rüsch, Moissy Cramayel, France) was 
inserted and the correct position confirmed using a fiberoptic bronchoscope 
(Intubation Fiberscope LF-2, Medical Systems and Endoscopes, Olympus 
Europe, Volketswil, Switzerland). Pressure-controlled ventilation with 5 cm 
water positive end-expiratory pressure and peak pressure < 30 cm water was 
used for both double-lung ventilation and OLV. Inspiratory oxygen fraction 
(FiO2) was set to 0.8 during double-lung ventilation and increased to 1.0 
during OLV or performance of bronchoalveolar lavage (BAL). For double-lung 
ventilation, tidal volumes up to 8 ml/kg and a respiratory frequency of 10 - 15 
/min were chosen in order to maintain PaCO2 between 35 – 45 mm of 
mercury. For OLV, tidal volumes up to 6 – 7 ml/kg with a respiratory frequency 
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of 10 – 20 /min were used with a FiO2 of 1.0 to ensure an oxygen saturation 
>85%. Patients requiring insufflation of oxygen, recruitment maneuver, or 
even intermittent continuous positive airway pressure on the deflated, non-
ventilated lung, were excluded from the analysis, as they did not fulfill the 
criteria for inclusion in the intention-to-treat population (OLV and alveolar 
hypoxia without reoxygenation [2 patients in each group]). 
Upon completion of surgery, re-ventilation of the previously non-
ventilated lung was performed (manual inflation for 10 sec to 30 cm water four 
times) and after discontinuation of anesthetic agents patients were extubated 
and taken directly to a recovery room or the intensive care unit for post-
anesthetic care. 
During anesthesia, invasive blood pressure measurements, 
electrocardiogram, heart rate, oxygen saturation, end-tidal carbon dioxide, 
central venous pressure, body temperature and diuresis were continuously 
monitored and recorded in both groups. Arterial blood gas analysis was 
performed as required. 
Crystalloids were used for hydration. Hydroxyethyl starch (130/0.4) and 
additional crystalloids were given according to clinical needs. None of the 
patient received blood transfusions. A perioperative antibiotic prophylaxis was 
given to all patients. 
 
Primary endpoints 
BALF and plasma 
Primary endpoints were inflammatory mediators in BALF. The first BAL was 
performed before OLV at the later deflated, non-ventilated lung undergoing 
surgery (T1), the second BAL immediately after re-expansion and re-
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ventilation of the same lung at the end of surgery (T2). At the same time 
points T1 and T2, 10 ml peripheral blood was collected from the arterial 
catheter (BD Vacutainer Systems, Preanalytical solutions, Belliver Industrial 
Estate, Plymouth PL6 7BP, UK) from the last 27 patients (14 patients from the 
propofol group, 13 patients from the sevoflurane group) (Fig. 1). Additionally, 
cells in BALF of these patients were determined quantitatively and 
qualitatively. 
In all patients, BAL was performed by flexible fiberoptic bronchoscopy 
under sterile conditions using sodium chloride 0.9% in an average of 150 ml 
per BAL. The tip of the bronchoscope was wedged into a sub-segment 
bronchus of the lung. The chosen segment was lavaged after instillation of 50 
ml of sterile saline solution (0.9%, pH 7.4), afterwards the lavage fluid was 
gently aspirated. This procedure was repeated two times in different sub-
segments. Recovery rate of the lavage fluid was approximately 50%. 
Both, BALF and blood samples were centrifuged (BALF: 10°C, 5 min. 
at 1500 rpm, Blood: 10°C, 10 min at 2000 rpm) and supernatants of BALF as 
well as plasma were stored at -20°C. Cell pellets from centrifuged BALF from 
27 patients were assessed for differential cell counts using cytospins and Diff-
Quick (Dade Behring, Duedingen, Switzerland). The difference of neutrophils 
at T2 minus T1 was calculated in percentages and analyzed in correlation to 
the difference in the concentration of inflammatory mediators in BALF. 
For analysis of human inflammatory mediators in BALF and plasma 
(TNF-, IL-1, IL-6, IL-8, MCP-1), enzyme-linked immunosorbent assays were 
used (TNF-: BD Biosciences Pharmingen, San Diego, CA; other enzyme-
linked immunosorbent assays: RD Systems, Minneapolis, MN).  
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Chemotaxis assays 
Human neutrophils from healthy donors were prepared by centrifugation 
through Ficoll gradients as described before 16. Purified neutrophils were 
labelled with 10 μM carboxylfluorescein diacetate succinimidyl ester for 15 min 
at 37°C (CFDA-SE, Invitrogen, Basel, Switzerland). Cells were washed twice 
with 0.9 % NaCl and resuspended in Ham’s 12 medium, 1 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, containing a 1:10 dilution of 
10% gelatin in H20, pH 7.2. After isolation, cells were allowed to adhere to 
glass coverslips for 15 min at 37°C. The coverslips were then rinsed and 
placed on Zigmond chambers 17. Aliquots (100 μl) of Dulbecco’s modified 
Eagle’s Medium (Invitrogen AG, Basel, Switzerland), supplemented with 1% 
fetal bovine serum, were added to one side of the chamber and the same 
solution containing N-formyl-methyl-leucyl-phenylalanine (10-5 M) was added 
to the other side as a positive control. The same experiments were performed 
with 100 μl of BALF from different patients on both sides of the chamber, 
whereby one patient of the propofol group was matched to one patient from 
the sevoflurane group with similar OLV time (6 matched pairs were tested).  
Time-lapsed videomicroscopy was used to examine neutrophil 
movements in Zigmond chambers. Neutrophils were recorded moving along a 
chemoattractant gradient in the chamber. The microscope was equipped with 
differential interference contrastoptics and a 10 x objective. Images were 
captured at 1 min intervals for 2 h with a LX Widefield high speed and highly 
sensitive microscope for live cell imaging (Leica, Solms, Germany). The 
system is built on an inverted microscope with fast filterwheels for excitation 
from ultraviolet to visible (e.g. Hoechst, GFP RFP, CFP, YFP, Cy5 and an EM-
CCD camera, Fura-2).  
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The recorded data were analysed using the spot tracking algorithm of 
the Imaris Software (Bitplane AG, Zurich, Switzerland). Displacement vectors 
were construed from the position of the track start to the position of the track 
end. The normalized displacement vectors were visualized in a scatter plot. 
The averaged displacement direction was calculated by taking the first 
principal component of the set of all direction vectors (i.e. the unit length 
vector v that maximizes sum(<v,d_i>^2), where d_i denotes the (normalized) 
displacement vectors). It was then plotted as superimposed arrow. For 
quantitative analysis of movement we calculated the counterclockwise angles 
in radians between the x-axis and the displacement vectors in 2-dimensional 
Euclidean space. The number of cells migrating in a specific direction 
(represented by the calculated angle of the displacement vector) was plotted 
as histogram figure. 
 
Secondary endpoints 
The clinical postoperative outcome was assessed as secondary endpoint 
based on adverse events. The following parameters were determined: CRP 
preoperatively (baseline, BL), on the 1st postoperative day (POD1), on the 3rd 
postoperative day (POD3), and on the 5th postoperative day (POD5). Also 
leukocyte count in the blood of the patients was registered at the same time 
points. 
 The following adverse events were defined during postoperative 
course: pulmonary infections requiring antibiotic treatment; radiographically 
diagnosed pneumonia; radiographically diagnosed atelectasis; 
radiographically diagnosed effusion; fistula; re-intubation; systemic 
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inflammatory response syndrome; sepsis; acute respiratory distress 
syndrome; surgical revision; death. 
 
Statistical analysis 
The intention-to-treat population comprised all patients with OLV and alveolar 
hypoxia without reoxygenation. This intention-to-treat population was used for 
the primary analysis. The sample size calculation was performed based on 
the estimate of a 40% difference in expression on inflammatory mediators at a 
5% level of statistical significance and a power of 80% (propofol group: mean 
value with standard deviation: 500  300; sevoflurane group: 300  200; 
assumption from in vitro data only). Based on these calculations 27 patients 
were required for each study group. To compensate for withdrawals, 70 
patients were enrolled in the study.  
 All analyses were carried out with the statistical software program 
SPSS (statistical package for the social sciences), release 12.0. Descriptive 
data are shown as median and interquartile range (IQR), mean and standard 
deviation, counts and percentage respectively. 
Differences between the propofol group and the sevoflurane group 
were tested by the Mann-Whitney U-test. Spearman’s rho was used to assess 
the associations between the variables. Comparisons between groups were 
controlled for type-I error rate using the Bonferroni correction for multiple 
comparisons: ' =  : m, whereas ' is the corrected level of significance,  
the unadjusted level of significance and m is the number of comparisons. 
Because of a significant difference in OLV time between the two groups 
comparisons were adjusted using OLV time as a covariate and MANCOVA. 
As the assumptions for this statistical procedure were not consistently met by 
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the data characteristics, the results should be interpreted with some caution. 
The outcomes of this procedure are therefore reported in parentheses and in 
a descriptive manner.  
A p-value < 0.05 was considered to be significant. 
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RESULTS 
 
Patient characteristics and surgical criteria 
A total of 54 patients were enrolled into the study with wedge resections as 
well as partial and total lobectomies. None of these patients showed any signs 
of preoperative infection. There were no differences in patient characteristics 
and surgical data between the two groups, except for a longer duration of OLV 
in the propofol (140 ± 76 min) vs. the sevoflurane group (98 ± 57 min, p< 0.05) 
(Tab. 1). The range of applied doses of fentanyl per patient was 0.2 – 4 mg in 
the propofol and 0.2 – 3.8 mg in the sevoflurane group. Similarly, no 
difference was found for remifentanil (0 – 5.1 mg versus 0 – 4.7 mg). In the 
propofol group, patients received between 400 and 3700 ml of cristalloids 
(600 – 3400 ml in the sevoflurane group), and between 0 and 1700 ml of 
hydroxyethyl starch (0 – 1500 ml in the sevoflurane group) with no statistically 
significant difference between both groups.   
 
Inflammatory mediator expression following OLV 
OLV resulted in an increase in the measured inflammatory mediators in both 
the propofol and the sevoflurane groups (calculated as difference in 
concentrations of inflammatory mediators in BALF, performed after OLV at T2, 
and before OLV at T1). However, the increase of inflammatory mediators 
upon OLV in the propofol group was significantly higher for all parameters 
except IL-1 compared with the sevoflurane group(p< 0.05) (Tab. 2, Fig. 2A – 
2E).  
The magnitude of cytokine expression also varied over the course of 
OLV (Fig. 3A – 3E). A progressive increase in TNF-, IL-6, IL-8, MCP-1 and 
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to a lesser degree also in IL-1 was observed with increasing duration of OLV. 
For all parameters except IL-1, this increase was again smaller in patients 
with sevoflurane anesthesia. Interestingly, the cytokine increase in the 
propofol group appeared to follow a linear pattern up to approximately 120 
min of OLV, while thereafter the magnitude of the expression increased to a 
larger degree and approaching an exponential fashion (Fig. 3C and 3D). This 
was also observed in patients receiving sevoflurane, however again a 
substantial attenuation compared with the propofol group was apparent. 
 
Cellular response to OLV 
OLV resulted in an increase in polymorphonuclear cells in BALF in both the 
propofol and the sevoflurane groups by approximately 10%. Interestingly, the 
increase in the inflammatory mediators  IL-1 IL-8, IL-6, and MCP-1 showed a 
significant correlation with accumulation of polymorphonuclear cells 
(determined as the difference of percentage of neutrophils in the lavage at T2 
minus percentage of neutrophils in the lavage at T1) in the propofol group, but 
not in the sevoflurane group. While for TNF- no correlation between 
neutrophil accumulation and mediator expression was observed for both 
groups (Fig. 4A), significant correlations in the propofol group were found for 
IL-1 (r = 0.281, p< 0.05) (Fig. 4B), IL-6 (r = 0.512, p< 0.005) (Fig. 4C) and 
IL-8 (0.466, p< 0.01) (Fig. 4D). However, in the sevoflurane group, such 
correlations were missing (IL-1: r = 0.024, n.s., IL-6: r = 0.091, n.s., IL-8: r = 
0.116, n.s.). Between neutrophils and MCP-1, also a known neutrophil 
chemoattractant, no correlation was observed in both groups (r = 0.157 and r 
= 0.009, n.s.) (Fig. 4E). While the lack of correlation in the sevoflurane group 
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compared to the propofol group might also reflect a consequence of the 
reduced inflammatory response in this group the differences between the 
correlations in the propofol group vs the sevoflurane group did not reach 
statistical significance. 
 To underline the biological relevance of the measured inflammatory 
mediators, BALF of a patient pair propofol – sevoflurane with similar OLV time 
was tested for chemotaxis activity. As shown in Fig. 5 neutrophils were 
attracted by the BALF of propofol patient (Fig. 5A). Fig. 5B and Fig. 5C 
reflect the positive control experiment with the N-formyl-methyl-leucyl-
phenylalanine. 
 
Clinical evaluation 
CRP and blood leukocyte count as additional parameters for 
inflammation were assessed preoperatively, on the 1st, 3rd, and 5th 
postoperative day, in order to determine possible differences in the 
sevoflurane compared to the propofol group. No statistically significant 
difference in CRP and leukocyte count could be detected between both 
anesthesia groups from the 1st to the 5th postoperative day (Tab. 3). 
Interestingly, as seen in Tab. 4, there was a significant correlation between 
CRP values and OLV time at the 1st postoperative day in the propofol group (r 
= 419; p< 0.05), which is decreased and not significant in the sevoflurane 
group (r = 0.226; n.s.). 
In order to obtain information about a possible secondary systemic 
inflammatory reaction about OLV, inflammatory mediators were determined in 
plasma before and immediately after OLV and differences (T2 – T1) were 
calculated. While plasma TNF-, IL-1, and IL-8 were not detectible at both 
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time points, plasma concentrations of IL-6 and MCP-1 were increased after 
OLV. We therefore correlated values from these mediators to CRP values of 
the 1st postoperative day (Tab. 5). A correlation of 0.459 was calculated 
between CRP value of the 1st postoperative day and increase of plasma IL-6 
concentration in the propofol group (p< 0.05), while no correlation was 
observed in the sevoflurane group (r = 0.324, n.s.). Similar data were found 
for the correlation between CRP and MCP-1: 0.535 in the propofol (p< 0.05), 
0.166 in the sevoflurane group (n.s.). 
 Adverse events are reported in Tab. 6. The overall number of adverse 
events in the propofol group was significantly higher than in the sevoflurane 
group (40 versus 18, p< 0.05). In addition, patients in the propofol spent 
significantly more time in the intensive care unit compared with patients in the 
sevoflurane group (1.52  2.33 d vs. 0.87  0.43 d, p< 0.05) (p-values 
adjusted to the difference of OLV time). 
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DISCUSSION 
 
Volatile anesthetics have been shown to have cardioprotective effects 11,18,19. 
While some studies have pointed out a protection using volatile anesthetics 
before the onset of injury, others also indicate that protection against injury is 
still achieved when administered after myocardial ischemia. Two clinical trials 
even showed cardioprotective effects of sevoflurane, when the anesthetics 
were used throughout cardiac surgery 20,21. We therefore were interested to 
explore potential protective benefits of sevoflurane compared with propofol 
anesthesia during thoracic surgery with OLV.  
Injury to cells or tissues related to an inflammatory response can be 
ascribed to a complex array of mediators generated and released from 
activated phagocytes such as neutrophils and macrophages or by target cells 
such as AEC. Cytokines and chemokines are implicated in the recruitment of 
effector cells toward target tissues, whereby TNF- and interleukins are 
strong neutrophil chemoattractants.  
Previous studies have shown attenuating effects of volatile anesthetics 
in a model of AEC injury. A study in rat AEC showed that exposure to volatile 
anesthetics altered secretion of inflammatory mediators upon IL-1 stimulation 
22. Halothane, isoflurane and enflurane decreased production of IL-6, 
macrophage inflammatory protein-2, and MCP-1 protein concentrations in a 
dose- and time-dependent manner. AEC are a potent source of inflammatory 
mediators within the respiratory compartment of the lung upon injury with 
endotoxins 23. Our group has therefore tested the effect of sevoflurane in an in 
vitro model of AEC stimulation 16. In a first step AEC were pre-exposed to 
sevoflurane, followed by a stimulation with endotoxin 13. Results of this study 
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demonstrated decreased expression of chemokines with attenuated 
chemotaxis. Exposing AEC first to endotoxin with a sevoflurane treatment 
after the onset of injury resulted again in attenuation of the inflammatory 
reaction 16.  
In the present clinical trial the production of the corresponding 
inflammatory mediators TNF-, IL-1, IL-6, IL-8, and MCP-1 in the respiratory 
compartment was quantitatively assessed upon OLV for thoracic surgery. It is 
shown that the increase of these mediators is diminished in the sevoflurane 
group compared with the propofol group. Based on these results, it appears 
that in the propofol group a significantly more pronounced inflammatory 
reaction is present. This clinical study suggests that the use of sevoflurane 
might have the potential to reduce AEC-induced inflammatory answer in OLV 
for thoracic surgery. Chemotaxis assays underlined the biological relevance of 
these observations.  
As we were also interested in assessing the biological consequences 
of this change of expression of mediators on a cellular level, we quantified 
neutrophils in BALF and possible relationships between cell influx and 
upregulation of mediators. Although MCP-1 is well known as a macrophage 
chemoattractant, it might also be responsible for neutrophil reruitment under 
certain conditions 7,8. The analyses showed a significant correlation of the 
increase in polymorphonuclear cells and the upregulation of IL-1, IL-6, and 
IL-8 in the propofol group, but not for TNF- and MCP-1. Under sevoflurane 
anesthesia, however, the inflammatory reaction, assessed by the magnitude 
of cytokine expression, was significantly attenuated and not correlated with 
the increase of polymorphonuclear cells in BALF. These results point at a 
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reduced inflammatory response at molecular and cellular level under 
sevoflurane anesthesia. 
A major finding of this study was the improved outcome for patients in 
the sevoflurane group, which showed approximately 50% less adverse events 
compared to the propofol patients. As our analysis had shown an almost 
exponential increase of inflammatory mediators in correlation to OLV time in 
the propofol group, we postulated a biological phenomenon of this 
observation, and therefore evaluated CRP and blood leukocyte count. 
Interestingly, a significant correlation was observed between CRP and OLV 
time in the propofol group, which was clearly attenuated in the sevoflurane 
one. Also CRP values at the 1st postoperative day were correlated with IL-6 
and MCP-1 under propofol anesthesia, while under sevoflurane anesthesia, 
the correlation was less accentuated and not significance. These data might 
point out a potential link between inflammatory mediators in the lung and 
outcome.  
Lung injury following thoracic surgery is relatively uncommon, but it is a 
major complication with high mortality 24,25. A recent study showed a 
combined frequency of acute lung injury/acute respiratory distress syndrome 
of 3.9% with a mortality of 72% for patients developing acute respiratory 
distress syndrome 26. Several factors need to be considered as possible 
triggers for development of acute lung injury in OLV for thoracic surgery: i) 
During OLV the operated lung remains completely atelectatic for a period of 
time, in parallel with hypoperfusion due to hypoxic vasoconstriction. Lung re-
expansion and tissue reperfusion might reflect an ischemia-reperfusion injury, 
which could explain the underlying mechanism of inflammation. ii) The 
postresectional remaining tissue has been subjected to considerable 
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mechanical manipulation during the conducted lobectomy or segmentectomy, 
also contributing to an inflammatory response. iii) Ventilation of the ventilated 
lung with a high inspiratory oxygen concentration during OLV could lead to an 
injury of both the ventilated and collapsed lung. iv) Mechanical ventilation itself 
can cause damage to the ventilated lung. The mechanisms are still not clear 
and the evidence for their involvement in acute lung injury after OLV is 
questionable 24,27,28. v) Re-expansion of the collapsed lung induces lung injury 
with increased microvascular permeability leading to re-expansion pulmonary 
edema 29,30. 
During OLV the deflated, alveolar hypoxia occurs in the non-ventilated 
lung. Recently, the involvement of AEC in hypoxia-induced lung injury has 
been shown in vitro 31. Hypoxia leads to enhanced expression of adhesion 
molecules on AEC with increased neutrophil adherence, demonstrating that 
the lower respiratory epithelial compartment might play an important role in 
inflammatory mechanisms during hypoxia-induced lung injury. In the present 
study a re-ventilation/reperfusion injury is rather unlikely as the lavage was 
performed immediately upon re-ventilation. Therefore, besides the above 
mentioned possible mechanisms i) – v), hypoxia could be added as a possible 
trigger inducing inflammatory reactions (vi).  
It is well known that upon OLV hypoxic vasoconstriction occurs in this 
lung to reduce ventilation-perfusion mismatch. The effect of this 
vasoconstriction on lung parenchyma is unclear; theoretically it results in 
consecutive tissue hypoxia. In a recent study focussing on lung injury upon 
OLV 32 the authors investigated the vascular compartment after 60 min of OLV 
in pigs and showed congested vasculature in the deflated, non-ventilated 
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lung. These findings from the vasculature together with our data from the 
respiratory tract would support the idea of compartmentalized inflammatory 
reactions. Mulligan et al. defined a compartmentalized role for inflammatory 
mediators in a model of intrapulmonary deposition of IgG immune complexes 
33. In addition, sevoflurane-induced attenuation of hypoxic pulmonary 
vasoconstriction itself might also influence the degree of injury.  
The duration of OLV seems to be essential as previously shown by 
Tekinbas et al. 34. This group randomly allocated rats into groups with different 
OLV periods. Lung tissue myeloperoxidase acitivity, defined as a parameter 
for neutrophils, increased in parallel with OLV time. Also histopathologic 
findings such as alveolar edema and infiltration of lung tissue with 
inflammatory cells were in accordance to the OLV time. These findings were 
also supported by Misthos et al., showing that magnitude of oxidative stress 
was related to OLV duration 35. Our data might support these findings. 
While Schilling et al. showed a beneficial effect of desflurane on the 
non-deflated, ventilated lung during OLV, this is the first study focusing on the 
possible benefit of the volatile anesthetic on the deflated, non-ventilated lung 
35. 
In summary, this prospective randomized study reveals an 
immunomodulatory role for the volatile anesthetic sevoflurane in patients 
undergoing OLV for thoracic surgery demonstrating a possible anti-
inflammatory effect. An important finding of the present study is that the 
sevoflurane group not only showed an attenuated inflammatory reaction at the 
organ level in the lung undergoing OLV, but also an improved postoperative 
course with significantly lower overall number of adverse events.  
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